Filtered By:
Condition: Atrial Fibrillation
Cancer: Cancer
This page shows you your search results in order of relevance. This is page number 7.
Order by Relevance | Date
Total 359 results found since Jan 2013.
EBN resources page
SIGN Apps for iPhone and iPad http://itunes.com/apps/signguidelines, https://play.google.com/store/apps/details?id=com.rootcreative.sign The SIGN app has recently been updated and now contains quick reference guides (QRGs) for:SIGN 136 Management of chronic pain SIGN 135 Management of epithelial ovarian cancer SIGN 134 Treatment of primary breast cancer SIGN 133 Management of hepatitis C The SIGN app has also had a complete re-design and now features:Optimisation for the latest operating systems Re-designed for improved legibility Send pdf button feature Split screen feature (ipad) Prevention of stroke in patients with atr...
Source: Evidence-Based Nursing - June 17, 2014 Category: Nursing Tags: Liver disease, General practice / family medicine, Hepatitis and other GI infections, Drugs: cardiovascular system, Pain (neurology), Stroke, Diet, Pregnancy, Reproductive medicine, Breast cancer, Gynecological cancer, Lung cancer (oncology), Radiotherapy Source Type: research
Relation between Cancer and Atrial Fibrillation (from The REasons for Geographic And Racial Differences in Stroke Study)
Atrial fibrillation (AF) is common in patients with life threatening cancer and those undergoing active cancer treatment. However, data from persons with a history of non-life threatening cancer and those who do not require active cancer treatment are lacking. A total of 15,428 (mean age: 66 ± 8.9 years; 47% women; 45% blacks) participants from the REasons for Geographic And Racial Differences in Stroke (REGARDS) with baseline data on prior cancer diagnosis and AF were included. Participants with life threatening cancer and active cancer treatment within 2 years of study enrollment were excluded.
Source: The American Journal of Cardiology - January 31, 2015 Category: Cardiology Authors: Wesley T. O’Neal, Susan G. Lakoski, Waqas Qureshi, Suzanne E. Judd, George Howard, Virginia Howard, Mary Cushman, Elsayed Z. Soliman Source Type: research
Rivaroxaban for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation and Active Cancer.
Rivaroxaban is broadly used for the primary prevention of stroke and systemic embolism in the general population with non-valvular atrial fibrillation (AF). However, there is little published evidence on the safety and efficacy of rivaroxaban for AF in patients with active cancer. The aim of this study was to assess the safety and efficacy of rivaroxaban in patients with active cancer and AF. Use of rivaroxaban in cancer patients at Memorial Sloan Kettering Cancer Center (MSKCC) is monitored in the setting of a Quality Assessment Initiative.
Source: The American Journal of Cardiology - April 26, 2017 Category: Cardiology Authors: Eva S. Laube, Anthony Yu, Dipti Gupta, Yimei Miao, Patrick Samedy, Jonathan Wills, Stephen Harnicar, Gerald A. Soff, Simon Mantha Source Type: research
Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer
Rivaroxaban is broadly used for the primary prevention of stroke and systemic embolism in the general population with nonvalvular atrial fibrillation (AF). However, there is little published evidence on the safety and efficacy of rivaroxaban for AF in patients with active cancer. The aim of this study was to assess the safety and efficacy of rivaroxaban in patients with active cancer and AF. The use of rivaroxaban in patients with cancer at the Memorial Sloan Kettering Cancer Center is monitored in the setting of a Quality Assessment Initiative.
Source: The American Journal of Cardiology - April 26, 2017 Category: Cardiology Authors: Eva S. Laube, Anthony Yu, Dipti Gupta, Yimei Miao, Patrick Samedy, Jonathan Wills, Stephen Harnicar, Gerald A. Soff, Simon Mantha Tags: Arrhythmias and Conduction Disturbances Source Type: research
The Impact of Body Weight on Mortality After Stroke—Reply
In Reply We appreciate the interest of Doehner and Audebert in our article on body mass index (BMI) and short-term stroke survival. However, they fail to relate to our article’s essential and central point: BMI in stroke patients is significantly associated with stroke severity (ie, higher BMI is associated with lesser stroke severity). This means that strokes associated with obesity are less severe than strokes of other causes (eg, atrial fibrillation). Stroke severity is the all-important determinant of short-term stroke survival. Thus, stroke severity is essential to examine differences in mortality after stroke betwe...
Source: JAMA Neurology - January 1, 2015 Category: Neurology Source Type: research
Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys ® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs) and bett er manage heart failure⁵ (NT-proBNP). Roche ' s introduction of five new intended uses for these existing, globally accepted diagnostic solutions means more people could benef...
Source: Roche Media News - April 28, 2021 Category: Pharmaceuticals Source Type: news
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Efficacy and Safety of Nonvitamin K Oral Anticoagulants in Patients with Atrial Fibrillation and Cancer: A Study-Level Meta-Analysis.
CONCLUSION: In AF patients with malignancy, NOACs appear at least as effective as VKAs in preventing thrombotic events and reduce intracranial bleeding. NOACs may represent a valid and more practical alternative to VKAs in this setting of high-risk patients.
PMID: 31785599 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 29, 2019 Category: Hematology Authors: Cavallari I, Verolino G, Romano S, Patti G Tags: Thromb Haemost Source Type: research
Vertebral artery stenosis predicts cerebrovascular diseases following radiotherapy for nasopharyngeal carcinoma
CONCLUSION: Our study found that NPC patients with vertebral artery stenosis, atrial fibrillation, or hypertension carry a higher risk for ischemic stroke or TIA. Regular assessment of vertebral artery after radiotherapy was suggested.PMID:35357575 | DOI:10.1007/s00520-022-07011-8
Source: Atherosclerosis - March 31, 2022 Category: Cardiology Authors: Chien-Fu Yeh Yu-Ching Chin Wei Hung Pin-I Huang Ming-Ying Lan Source Type: research
From cryptogenic to ESUS: Toward precision medicine?
Rev Neurol (Paris). 2022 May 18:S0035-3787(22)00592-6. doi: 10.1016/j.neurol.2022.01.016. Online ahead of print.ABSTRACTCryptogenic infarctions are infarctions without a defined cause, despite a complete work-up. They differ from infarctions of undetermined causes, which may involve overlapping causes or an incomplete investigation. It is also different from uncommon heritable and non-heritable causes. The term embolic stroke of undetermined source (ESUS) proposed in 2014 is defined as a non-lacunar brain infarct without proximal arterial stenosis or cardioembolic sources. The major advantage of this definition compared to...
Source: Revue Neurologique - May 21, 2022 Category: Neurology Authors: S Timsit Source Type: research
Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation and Cancer
CONCLUSIONS: Within our cohort, LAAO in cancer patients was achieved with good procedural success and offered a reduction in stroke at no increased bleeding risk similar to noncancer patients.PMID:37144110 | PMC:PMC10152198 | DOI:10.1016/j.jaccao.2022.10.016
Source: Cancer Control - May 5, 2023 Category: Cancer & Oncology Authors: Samuel A Shabtaie Nicholas Y Tan Robert C Ward Bradley R Lewis Eric H Yang David R Holmes Joerg Herrmann Source Type: research
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
